Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Tykerb lapatinib: Preliminary Phase II data

Preliminary data from the first 49 patients in an extension of the open-label, international Phase II EGF105084 trial

Read the full 181 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE